Clinical Trial Update: Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19 [Phase 2]

View source ↗

Summary

The Phase 2 trial of cysteamine-pantetheine disulfide (TTI-0102) for mild to moderate COVID-19 has been withdrawn by the sponsor, Thiogenesis Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Cysteamine-pantetheine disulfide (cysteamine-pantetheine disulfide)

Snippet

Sponsor: Thiogenesis Therapeutics, Inc. | Conditions: COVID-19, COVID-19 Acute Respiratory Distress Syndrome | Phase 2 | Status: WITHDRAWN